Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
RAS/RAF mutations
Description:
Genetic alterations in RAS or RAF genes that can alter growth-regulating signaling and contribute to cancer.
Primary topic:
Colorectal Cancer Treatments and Studies (29%)
Related topics:
Colorectal Cancer Treatments and Studies (29%),
Melanoma and MAPK Pathways (12%),
HER2/EGFR in Cancer Research (9%)
OpenAlex ID:
keywords/ras-raf-mutations
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
2017
·
Moritz Schütte
, Thomas Risch
, et al.
·
Nature Communications
·
362
PDF
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
2009
·
Martin L. Sos
, Stefanie Fischer
, et al.
·
Proceedings of the National Academy of Sciences
·
281
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
2017
·
Nathan O. Siemers
, James L Holloway
, et al.
·
PLoS ONE
·
225
PDF
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
2012
·
Kenneth D. Rice
, Naing Aay
, et al.
·
ACS Medicinal Chemistry Letters
·
194
Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
2014
·
Vicky S. Sabine
, Cheryl Crozier
, et al.
·
Journal of Clinical Oncology
·
136
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
2023
·
Joris van de Haar
, Xuhui Ma
, et al.
·
Nature Medicine
·
96
PDF
Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
2017
·
J Xu
, N Pfarr
, et al.
·
Oncogenesis
·
95
PDF
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors withRAS/RAFAlterations
2019
·
Aditya Bardia
, Mrinal Gounder
, et al.
·
The Oncologist
·
94
PDF
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
2017
·
R. Cohen
, O. Buhard
, et al.
·
European Journal of Cancer
·
93
PDF
Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data
2018
·
Anne Trinh
, Claudia Lädrach
, et al.
·
British Journal of Cancer
·
88
PDF
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
2014
·
Lisa Zimmer
, Fabrice Barlesi
, et al.
·
Clinical Cancer Research
·
79
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
·
Suzanne Leijen
, Mark R. Middleton
, et al.
·
Clinical Cancer Research
·
73
Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma
2019
·
Odise Cenaj
, Azra H Ligon
, et al.
·
American Journal of Clinical Pathology
·
66
PDF
HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
2021
·
Kimio Yonesaka
·
Cancers
·
62
PDF
Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study
2023
·
Xue Hou
, Chengzhi Zhou
, et al.
·
Journal of Thoracic Oncology
·
61
PDF
Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma
2020
·
M. Herman Chui
, Amir Momeni Boroujeni
, et al.
·
Modern Pathology
·
43
Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making
2017
·
R.P. Jones
, K.W. Brudvik
, et al.
·
European Journal of Surgical Oncology
·
43
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
2013
·
Karen Kelly
, Julien Mazieres
, et al.
·
Journal of Clinical Oncology
·
43
Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems
2013
·
Teddy S Nagaria
, Julia L Williams
, et al.
·
Neoplasia
·
41
PDF
Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation
2010
·
Gabriela I. Rozenberg
, Kimberly B. Monahan
, et al.
·
Melanoma Research
·
40
Personalizing Therapy for Colorectal Cancer
2013
·
Ashley Wong
, Brigette B.Y. Ma
·
Clinical Gastroenterology and Hepatology
·
38
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
2019
·
Vijay G. Ramakrishnan
, Kevin C. Miller
, et al.
·
Haematologica
·
37
PDF
Low prevalence of RAS‐RAF‐activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions
2007
·
James O. Indsto
, Swapna Kumar
, et al.
·
Journal of Cutaneous Pathology
·
37
MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy
2016
·
Tomoko Tanaka
, Mayumi Higashi
, et al.
·
Journal of Pediatric Surgery
·
36
Kinase domain activation through gene rearrangement in multiple myeloma
2018
·
Gareth J Morgan
, Jie He
, et al.
·
Leukemia
·
35
PDF
Show more works
View as search
Works count:
188
Citation count:
3,138
Year
Topic
Type